TrialSignal
Clinical trial intelligence report
A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02075463
Status
TERMINATED
Phase
Phase 2a
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
The clinical trial evaluated GSK1278863 for treating anemia in patients with chronic kidney disease who are hyporesponsive to rhEPO. The study aimed to assess the drug's safety and efficacy over a 16-week treatment period, following a 4-week run-in with rhEPO. The trial was sponsored by GlaxoSmithKline and included 15 participants, with a focus on optimizing hemoglobin levels.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02075463
Indication
Anemia
Modality
small molecule
Target
Anemia in hemodialysis-dependent chronic kidney disease patients
Intervention
GSK1278863, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.